185 related articles for article (PubMed ID: 31808285)
1. Is there any correlation between spectral CT imaging parameters and PD-L1 expression of lung adenocarcinoma?
Chen ML; Shi AH; Li XT; Wei YY; Qi LP; Sun YS
Thorac Cancer; 2020 Feb; 11(2):362-368. PubMed ID: 31808285
[TBL] [Abstract][Full Text] [Related]
2. Can spectral computed tomography imaging improve the differentiation between malignant and benign pulmonary lesions manifesting as solitary pure ground glass, mixed ground glass, and solid nodules?
Chen ML; Li XT; Wei YY; Qi LP; Sun YS
Thorac Cancer; 2019 Feb; 10(2):234-242. PubMed ID: 30582292
[TBL] [Abstract][Full Text] [Related]
3. Spectral CT imaging parameters and Ki-67 labeling index in lung adenocarcinoma.
Chen M; Li X; Wei Y; Qi L; Sun YS
Chin J Cancer Res; 2020 Feb; 32(1):96-104. PubMed ID: 32194309
[TBL] [Abstract][Full Text] [Related]
4. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
[TBL] [Abstract][Full Text] [Related]
5. Correlation with Spectral CT Imaging Parameters and Occult Lymph Nodes Metastases in Sufferers with Isolated Lung Adenocarcinoma.
Liu Y; Nie Y
Contrast Media Mol Imaging; 2022; 2022():5472446. PubMed ID: 35833081
[TBL] [Abstract][Full Text] [Related]
6. High expression level of interleukin-1β is correlated with poor prognosis and PD-1 expression in patients with lung adenocarcinoma.
Ding X; Zhang J; Shi M; Liu D; Zhang L; Zhang R; Su B; Ai K
Clin Transl Oncol; 2021 Jan; 23(1):35-42. PubMed ID: 32472456
[TBL] [Abstract][Full Text] [Related]
7. Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.
Qin T; Xia J; Liu S; Wang J; Liu H; Zhang Y; Jia Y; Li K
Thorac Cancer; 2020 May; 11(5):1139-1148. PubMed ID: 32154654
[TBL] [Abstract][Full Text] [Related]
8. Factors correlating the expression of PD-L1.
Lu F; Wang E; Liu H
BMC Cancer; 2024 May; 24(1):642. PubMed ID: 38796458
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.
Reiniger L; Téglási V; Pipek O; Rojkó L; Glasz T; Vágvölgyi A; Kovalszky I; Gyulai M; Lohinai Z; Rásó E; Tímár J; Döme B; Szállási Z; Moldvay J
Acta Oncol; 2019 Aug; 58(8):1087-1094. PubMed ID: 31002007
[No Abstract] [Full Text] [Related]
11. Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma.
Hu B; Xiao J; Xiu Y; Fu Z; Shi H; Cheng D
Nucl Med Commun; 2020 Mar; 41(3):252-259. PubMed ID: 32068670
[TBL] [Abstract][Full Text] [Related]
12. Preliminary exploration of the correlation between spectral computed tomography quantitative parameters and spread through air spaces in lung adenocarcinoma.
Song H; Cui S; Zhang L; Lou H; Yang K; Yu H; Lin J
Quant Imaging Med Surg; 2024 Jan; 14(1):386-396. PubMed ID: 38223127
[TBL] [Abstract][Full Text] [Related]
13. The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma.
Wu T; Zhou F; Soodeen-Lalloo AK; Yang X; Shen Y; Ding X; Shi J; Dai J; Shi J
Clin Lung Cancer; 2019 Mar; 20(2):e195-e207. PubMed ID: 30514666
[TBL] [Abstract][Full Text] [Related]
14. Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma.
Toyokawa G; Takada K; Okamoto T; Kawanami S; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Katsura M; Yamada Y; Shoji F; Baba S; Kamitani T; Oda Y; Honda H; Maehara Y
Ann Thorac Surg; 2017 Jun; 103(6):1750-1757. PubMed ID: 28347537
[TBL] [Abstract][Full Text] [Related]
15. Solid histological component of adenocarcinoma might play an important role in PD-L1 expression of lung adenocarcinoma.
Miyazawa T; Morikawa K; Otsubo K; Sakai H; Kimura H; Chosokabe M; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
Thorac Cancer; 2022 Jan; 13(1):24-30. PubMed ID: 34811933
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
[TBL] [Abstract][Full Text] [Related]
17. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
[TBL] [Abstract][Full Text] [Related]
18. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.
Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K
J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
[TBL] [Abstract][Full Text] [Related]
20. Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
Yoon N; Kim J; Maeng LS; Ahn JH; Park ES
Anticancer Res; 2018 Oct; 38(10):6003-6008. PubMed ID: 30275232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
